Cargando…

Reassessment of the dementia diagnosis of Alzheimer's disease in patients enrolled on the cholinesterase inhibitors dispensation program

OBJECTIVE: Reassess the diagnosis of Alzheimer's Disease (AD) in patients treated with anti-cholinesterases dispensed by High Cost Drug stores (Exceptional Drugs Program). METHODS: A prospective study to reassess the diagnosis of probable Alzheimer's Disease was conducted (AD). The patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piovesana, Magda Cristina Flaitt Sanches, Garcia, Fúlvio Rogério, Carrasco, Kátia G., Tognola, Waldir Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação de Neurologia Cognitiva e do Comportamento 2012
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619340/ https://www.ncbi.nlm.nih.gov/pubmed/29213808 http://dx.doi.org/10.1590/S1980-57642012DN06040012

Ejemplares similares

Reassessing blood acetylcholinesterase in dementia
por: Han, Pengcheng
Publicado: (2015)

Cholinesterase inhibitors as Alzheimer's therapeutics
por: Sharma, Kamlesh
Publicado: (2019)

Serum Concentrations of Cholinesterase Inhibitors in Patients With Alzheimer’s Dementia Are Frequently Below the Recommended Levels
por: Ortner, Marion, et al.
Publicado: (2020)

Reassessment of Pioglitazone for Alzheimer’s Disease
por: Saunders, Ann M., et al.
Publicado: (2021)

Systematic Review of Cholinesterase Inhibitors on Cognition and Behavioral Symptoms in Patients of Chinese Descent with Alzheimer’s Disease, Vascular Dementia, or Mixed Dementia
por: Leung, Ka-Chun, et al.
Publicado: (2017)

Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias
por: Muayqil, Taim, et al.
Publicado: (2012)

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
por: Hu, Ziheng, et al.
Publicado: (2018)

Medicare Advantage Enrollment and Disenrollment Among Persons With Alzheimer Disease and Related Dementias
por: James, Hannah O., et al.
Publicado: (2023)

RBC acetyl cholinesterase: A poor man's early diagnostic biomarker for familial alzheimer's and Parkinson's disease dementia
por: Bawaskar, Himmatrao Saluba, et al.
Publicado: (2015)

Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer’s Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients
por: Blanco-Silvente, Lídia, et al.
Publicado: (2017)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia
por: Hoffmann, Falk, et al.
Publicado: (2011)

Cholinesterase inhibitors for the treatment of dementia: real-life data in Hungary
por: Balázs, Nóra, et al.
Publicado: (2021)

Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis
por: Meng, Yan-Hong, et al.
Publicado: (2019)

OUTCOMES OF DISCONTINUING CHOLINESTERASE INHIBITORS IN NURSING HOME RESIDENTS WITH SEVERE DEMENTIA
por: Niznik, Joshua D, et al.
Publicado: (2019)

Effects of cholinesterase inhibition on attention and working memory in Lewy body dementias
por: Fallon, Sean James, et al.
Publicado: (2023)

Alzheimer's disease and Type 2 diabetes mellitus: the cholinesterase connection?
por: Allam, Appa Rao, et al.
Publicado: (2006)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease
por: Weng, Pei-Hsuan, et al.
Publicado: (2013)

Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer’s Disease
por: Hussein, Weiam, et al.
Publicado: (2018)

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease
por: Motter, Jeffrey N., et al.
Publicado: (2021)

Reassessing the Reassessment of suPAR in Glomerular Disease
por: Meijers, Björn K. I., et al.
Publicado: (2015)

Important Error in ‘Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias’ by Muayqil and Camicioli
por: Tariot, Pierre N., et al.
Publicado: (2014)

Persistence of Cholinesterase Inhibitor Treatment in Dementia: Insights from a Naturalistic Study
por: Olazarán, Javier, et al.
Publicado: (2013)

Concomitant Cholinesterase Inhibitor and Anticholinergic Drug Use Among Older Adults With Dementia
por: Carter, Elizabeth, et al.
Publicado: (2020)

Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer’s Disease
por: Schino, Ignazio, et al.
Publicado: (2022)

Cholinesterase Research
por: Korabecny, Jan, et al.
Publicado: (2021)

Effect of Multi-Month Dispensing on Viral Suppression for Newly Enrolled Adolescents and Adults in Northern Nigeria
por: Semo, Bazghina-Werq, et al.
Publicado: (2023)

Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada
por: Ali, Thibault B., et al.
Publicado: (2015)

A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease
por: S. Schneider, Lon
Publicado: (2000)

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
por: Rountree, Susan D, et al.
Publicado: (2009)

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
por: Farrimond, Lucy E, et al.
Publicado: (2012)

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
por: Wattmo, Carina, et al.
Publicado: (2012)

Screening and analysis of acetyl-cholinesterase (AChE) inhibitors in the context of Alzheimer's disease
por: Khan, Mohd. Babu, et al.
Publicado: (2018)

Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
por: Amat-ur-Rasool, Hafsa, et al.
Publicado: (2021)

Effect of QT Prolongation in Patients Taking Cholinesterase Inhibitors (Donepezil) for Alzheimer’s Disease
por: Kuwahata, So, et al.
Publicado: (2021)

Development of substituted benzylidene derivatives as novel dual cholinesterase inhibitors for Alzheimer's treatment
por: Gupta, Shraddha Manish, et al.
Publicado: (2023)

Trefoil Factor 3, Cholinesterase and Homocysteine: Potential Predictors for Parkinson’s Disease Dementia and Vascular Parkinsonism Dementia in Advanced Stage
por: Zou, Jing, et al.
Publicado: (2018)

Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
por: Zuroff, Leah, et al.
Publicado: (2017)

Anticholinergic Drug Burden in Persons with Dementia Taking a Cholinesterase Inhibitor: The Effect of Multiple Physicians
por: Reppas‐Rindlisbacher, Christina E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nf81rclauc2l3q42muv2cs7tjv